iSERA Lifesciences Q1FY27 net loss widens to ₹33.62 lakh on zero revenue
iSERA Lifesciences Ltd reported a standalone net loss of ₹33.62 lakh for Q1FY27, reversing the ₹54.98 lakh profit from Q4FY26. With zero revenue and persistent other expenses of ₹31.31 lakh, the company's reserves deteriorated to ₹(49.81) lakh.
*this image is generated using AI for illustrative purposes only.
iSERA Lifesciences reported a standalone net loss of ₹33.62 lakh for the quarter ended June 30, 2026 (Q1FY27), marking a significant deterioration from the ₹54.98 lakh profit posted in the preceding quarter. The company recorded zero revenue from operations and zero other income during the period, resulting in a complete absence of top-line growth. Total expenses for the quarter amounted to ₹33.62 lakh, leading to a basic earnings per share (EPS) of ₹(1.60), compared to ₹1.58 in Q4FY26.
The Board of Directors, including Managing Director Jayshree Suresh Jain, approved the unaudited financial results on August 7, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the independent auditor, G M K S & Co, Chartered Accountants, in accordance with Standard on Review Engagements (SRE 2410). The company operates in the IT/ITES sector and has no separate reportable segments under Ind AS-108.
Financial Performance
The financial statement highlights a stark contrast between the current quarter and the previous period. While iSERA Lifesciences generated ₹116.18 lakh in revenue from operations in Q4FY26, this figure dropped to nil in Q1FY27. Other income also ceased, falling from ₹5.77 lakh to zero. Despite the lack of revenue, the company incurred expenses totaling ₹33.62 lakh.
| Particulars | Q1FY27 (₹ Lakh) | Q4FY26 (₹ Lakh) | Q1FY26 (₹ Lakh) | FY26 (₹ Lakh) |
|---|---|---|---|---|
| Revenue From Operations | - | 116.18 | - | 135.50 |
| Other Income | - | 5.77 | - | 7.02 |
| Total Revenue | - | 121.95 | - | 142.52 |
| Employee Benefits Expense | 2.31 | 4.03 | - | 5.25 |
| Other Expenses | 31.31 | 55.24 | 1.54 | 103.63 |
| Total Expenses | 33.62 | 59.27 | 1.54 | 108.88 |
| Net Profit / (Loss) | (33.62) | 54.98 | (1.54) | 25.94 |
What the Numbers Show
The most critical aspect of this filing is the divergence between revenue generation and cost structure. In Q4FY26, the company maintained a positive operating margin with revenues significantly outpacing expenses. In Q1FY27, the cessation of revenue operations did not lead to a proportional reduction in costs. "Other Expenses" remained substantial at ₹31.31 lakh, accounting for nearly 93% of total quarterly outflows. This suggests that fixed or semi-fixed operational costs continue to be incurred despite the lack of business activity, eroding the reserves which now stand at ₹(49.81) lakh, a deterioration from ₹(16.19) lakh at the end of FY26. The paid-up equity share capital remains unchanged at ₹840.90 lakh.
Historical Stock Returns for iSERA Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | +3.01% | +409.20% | +3,334.37% | +20,457.14% |
What specific strategic initiatives or cost-cutting measures is iSERA Lifesciences planning to implement to reverse the trend of zero revenue and rising expenses?
How does the company intend to fund its ongoing operational costs given the depletion of reserves to ₹(49.81) lakh and the absence of top-line growth?
Are there any pending contracts, regulatory approvals, or product launches expected in Q2FY27 that could restore revenue generation from operations?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
